Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
32 results about "Cardiac ischaemia" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Ischemia is a condition in which the blood flow (and thus oxygen) is restricted or reduced in a part of the body. Cardiac ischemia is the name for decreased blood flow and oxygen to the heart muscle.
Patient monitor for determining a probability that a patient has acute cardiac ischemia
InactiveUS6532381B2Restricts transferabilityElectrocardiographyEvaluation of blood vesselsCardiac ischaemiaElectrocardiograph lead
A patient monitor for determining a probability that a patient has acute cardiac ischemia including an input device connectable to a patient to acquire electrocardiogram (ECG) signals from the patient, an instrumentation amplifier connected to the input terminal to combine the signals and to generate at least one ECG lead, and an analysis module. The analysis module is operable to continuously read the ECG lead, to analyze a portion of the ECG lead for a period of time, and to calculate a probability that the patient has acute cardiac ischemia based at least in part on the analyzed portion of the ECG lead.
Owner:GE MEDICAL SYST INFORMATION TECH
Chinese medicine adhesive film for preventing and treating coronary heart disease and angina pectoris and its preparing method
The Chinese medicine adhesive film for preventing and treating coronary heart disease and angina pectoris consists of back lining material, medicine layer and protecting film. The medicine layer consists of skeleton supplementary material, effective Chinese medicine extractive and plasticizer; and the effective Chinese medicine extractive is ointment of extractive of Chuanxiong rhizome, sandalwood, nutagrass flatsedge rhizome, dalbergia wood, frankincense, kudzu vine root, etc. The Chinese medicine adhesive film is adhered to left chest for transdermal absorption to act on heart, and can dilate coronary blood vessel, improve blood flow of coronary blood vessel, improve heart function and prevent hidden coronary heart disease.
Owner:马德林
Preparation method of agilawood health-care wine and agilawood wine thereof
InactiveCN103571704AGood health effectSimple componentsAlcoholic beverage preparationMedicineAgarwood
The invention discloses a preparation method of agilawood health-care wine, which comprises the following steps: 1) raw material preparation; 2) infusion; 3) finished product preparation, that is, filtering and checking infused liquid, then bottling and sealing to prepare the agilawood health-care wine. The invention also discloses agilawood wine prepared by the method. The method provided by the invention is simple in preparation process, easy to realize, high in production efficiency, and capable of rapidly preparing agilawood health-care wine with good health-care effect. The agilawood wine provided in the invention is simple in raw material components, and reasonable in combination, and gives full and effective play to pharmacological effects of agilawood, which means that fragrance and pharmacological components of agilawood are effectively diffused into the wine; the wine has the efficacy of inhibiting mycobacterium tuberculosis, organizing central nervous system, calming, relieving cough, reducing high blood pressure, and resisting heart ischemia, and thus has the effect of health care.
Owner:苗丽荣 +1
Patient monitor for determining a probability that a patient has acute cardiac ischemia
InactiveUS20020133087A1Restricts transferabilityElectrocardiographyEvaluation of blood vesselsCardiac ischaemiaElectrocardiograph lead
A patient monitor for determining a probability that a patient has acute cardiac ischemia including an input device connectable to a patient to acquire electrocardiogram (ECG) signals from the patient, an instrumentation amplifier connected to the input terminal to combine the signals and to generate at least one ECG lead, and an analysis module. The analysis module is operable to continuously read the ECG lead, to analyze a portion of the ECG lead for a period of time, and to calculate a probability that the patient has acute cardiac ischemia based at least in part on the analyzed portion of the ECG lead.
Owner:GE MEDICAL SYST INFORMATION TECH
Systems and Methods for Use By an Implantable Medical Device for Detecting and Discriminating Stroke and Cardiac Ischemia Using Electrocardiac Signals and Hemodynamic Parameters
ActiveUS20110224555A1Reduce of permanent impairmentTo offer comfortElectrocardiographyCatheterEcg signalCardiac ischaemia
Techniques are provided for detecting and distinguishing stroke and cardiac ischemia within a patient using an implantable medical device. In one example, a preliminary indication of stroke is detected by a pacemaker or similar implantable device based on an analysis of features of an intracardiac electrogram (IEGM) sensed by the device. Exemplary IEGM features indicative of possible stroke include the onset of prominent U-waves, the onset of notched T-waves, and changes in ST segment duration or QT duration. Upon detection of a possible stroke, the device then detects one or more hemodynamic parameters that are typically affected by cardiac ischemia. Such hemodynamic parameters can include, e.g., cardiac contractility or stroke volume. The device then distinguishes stroke and cardiac ischemia from one another based on whether any changes detected in the hemodynamic parameters are consistent with cardiac ischemia. Implantable systems that exploit subcutaneous electrocardiograms (ECGs) rather than IEGMs are also described.
Owner:PACESETTER INC
Treatment of diabetes and diabetic complications with NHE-1 inhibitors
This invention relates to methods of treating or preventing type 2 diabetes, diabetic neuropathy, diabetic cardiomyopathy, cataracts, diabetic retinopathy, foot ulcers, diabetic microangiopathy, diabetic macroangiopathy, diabetic ischemia reperfusion injury, diabetic cardiac ischemia reperfusion injury and / or insulin resistance syndrome (IRS) in mammals, particularly in humans, by administering a sodium-hydrogen exchanger type 1 (NHE-1) inhibitor or a pharmaceutical composition containing such an inhibitor. This invention also relates to combinations comprising NHE-1 inhibitors and a second pharmaceutical agent, said combinations being useful in treating type 2 diabetes, IRS, diabetic neuropathy, diabetic cardiomyopathy, cataracts, diabetic retinopathy, foot ulcers, diabetic ischemia reperfusion injury, diabetic cardiac ischemia reperfusion injury, diabetic microangiopathy and / or diabetic macroangiopathy.
Owner:PFIZER INC
Real-time biosignal measurement apparatus for cardiac ischemia and reperfusion
InactiveUS20150309013A1Keep the pressureLow operation potentialBiological material analysisDead animal preservationCardiac ischaemiaPeristaltic pump
The present invention relates to a real-time biosignal measurement apparatus for cardiac ischemia and reperfusion. The apparatus includes: a peristaltic pump which pumps perfusate from a tank storing the perfusate; a pressure trap which offsets the pulsation of both sides between a solution chamber temporarily storing the pumped perfusate and the perfusate tank; a heat exchanger to which the temporarily stored perfusate is applied and which transfers the heat of the perfusate; a bubble trap to which the heat transferred perfusate is applied on one side and which filters the heat transferred perfusate to transduce the perfusate to an isolated heart connected to the other side; a sensor unit which detects the gas concentration value in the myocardium of the isolated heart in real time during the cardiac ischemia reperfusion; and a control unit which is supplied with the gas concentration value in the myocardium of the isolated heart in order to analyze its correlation with the degree of a myocardial injury of the isolated heart.
Owner:UNIV IND COOP GRP OF KYUNG HEE UNIV
Systems and methods for distinguishing cardiac ischemia from systemic influences on IEGM morphology using an implantable medical device
ActiveUS8265739B1Prevent heart rateReduce deliveryElectrocardiographySensorsAcute hyperglycaemiaEcg signal
Techniques are provided for use in a pacemaker or implantable cardioverter / defibrillator (ICD) for distinguishing cardiac ischemia from other conditions affecting the morphology of electrical cardiac signals sensed within a patient, such as hypoglycemia, hyperglycemia or other systemic conditions. In one example, the device detects changes in morphological features of cardiac signals indicative of possible cardiac ischemia within the patient, such as changes in ST segment elevation within an intracardiac electrogram (IEGM). The device determines whether the changes in the morphological features are the result of spatially localized changes within a portion of the heart and then distinguishes cardiac ischemia from other conditions affecting the morphology of electrical cardiac signals based on that determination. In another example, the device exploits the interval between the peak of a T-wave (Tmax) and the end of the T-wave (Tend). A significant increase in the Tend−Tmax interval is indicative of ischemia rather than a systemic condition.
Owner:PACESETTER INC
Application of nicotinamide adenine dinucleotide in preparation of drug for preventing and treating heart ischemic injuries
InactiveCN105168236AProtectiveReduced infarct volumeOrganic active ingredientsCardiovascular disorderCardiac ischaemiaAdditive ingredient
The invention relates to application of nicotinamide adenine dinucleotide as an active ingredient in preparation of a drug for preventing or treating heart ischemic injuries. In experiments, caudal vein normal saline injection and a heart ischemia operation are carried out on rats in a control group, it is found through research results that a great number of apoptosis signals (TUNEL positive signals) appear on the hearts, while apoptosis signals of rats, on which caudal vein NAD+solution injection is carried out, in an experiment group can be effectively reduced.
Owner:SHANGHAI CHEST HOSPITAL
Systems and methods for use by an implantable medical device for detecting and discriminating stroke and cardiac ischemia using electrocardiac signals and hemodynamic parameters
ActiveUS8467864B2Mitigation of impairmentReduce riskElectrocardiographyCatheterEcg signalCardiac ischaemia
Techniques are provided for detecting and distinguishing stroke and cardiac ischemia within a patient using an implantable medical device. In one example, a preliminary indication of stroke is detected by a pacemaker or similar implantable device based on an analysis of features of an intracardiac electrogram (IEGM) sensed by the device. Exemplary IEGM features indicative of possible stroke include the onset of prominent U-waves, the onset of notched T-waves, and changes in ST segment duration or QT duration. Upon detection of a possible stroke, the device then detects one or more hemodynamic parameters that are typically affected by cardiac ischemia. Such hemodynamic parameters can include, e.g., cardiac contractility or stroke volume. The device then distinguishes stroke and cardiac ischemia from one another based on whether any changes detected in the hemodynamic parameters are consistent with cardiac ischemia. Implantable systems that exploit subcutaneous electrocardiograms (ECGs) rather than IEGMs are also described.
Owner:PACESETTER INC
Method and system for evaluating cardiac ischemia with an exercise protocol
InactiveUS7104961B2Easy to detectHigh peak heart rateElectrocardiographyCatheterDecreasing heart rateData set
A method of assessing cardiac ischemia in a subject to provide a measure of cardiac or cardiovascular health in that subject is described herein. The method comprises the steps of: (a) collecting a first RR-interval data set from said subject during a stage of gradually increasing heart rate up to a predetermined heart rate of at least 130 beats per minute; (b) collecting a second RR-interval data set from said subject during a stage of gradually decreasing heart rate; (c) comparing said first RR-interval data set to said second RR-interval data set to determine the difference between said data sets; and (d) generating from said comparison of step (c) a measure of cardiac ischemia during stimulation in said subject, wherein a greater difference between said first and second data sets indicates greater cardiac ischemia and lesser cardiac or cardiovascular health in said subject.
Owner:MEDIWAVE STAR TECH
Application of lecithin superoxide dismutase composite in preparation of medicines for treating and/or preventing cardiac ischemic injury
InactiveCN101966334AReduce infarct sizeEasy to shrinkPeptide/protein ingredientsAntinoxious agentsCardiac ischaemiaPorcine coronary artery
The invention relates to application of a lecithin superoxide dismutase composite in preparation of medicines for treating and / or preventing cardiac ischemic injury, wherein the lecithin superoxide dismutase composite is dipolymer combined with different molecule numbers of lecithin, and the concrete method comprises the following steps of: establishing a cardiac ischemic injury animal model; preparing a cardiac injury induced model for verifying a function of the cardiac ischemic injury animal model in cardiac protection treatment under the asepsis condition, spreading sacculus, blocking the sacculus for a long time and loosening the sacculus through injecting a contrast agent into the small pig coronary artery left anterior descending branch balloon implant so as to respectively establish a myocardial infarction model and a myocardial injury model through blood liquid infusion; and injecting the lecithin superoxide dismutase composite containing different molecule numbers of lecithin into the animal model so as to observe a new function of treating cardiac injury.
Owner:BEIJING TIDE PHARMA
Automated monitoring of myocardial function by ultrasonic transducers positioned on the heart
InactiveUS20110046488A1Promote contractionInduce ischaemiaDiagnostic probe attachmentCatheterCardiac ischaemiaUltrasonic sensor
The invention relates to a method and a post-operative care unit for analysing and quantifying an ultrasound tissue Doppler imaging (TDI) signal from a transducer fastened on the myocardium to obtain a parameter indicating regional cardiac ischaemia or correlates with global hypokinetic heart function. This has the advantage over manually operated probes that it can be automated and used continuously over long time. According to the method, a TDI signal trace corresponding to at least one of tissue velocity, strain or strain rate is extracted and correlated with an electrocardiogram to define subsections within a cardiac cycle in the extracted trace corresponding to the early systolic phase and the post-systolic phase. Then, a velocity, strain or strain rate is read in at least the post-systolic phase of the extracted trace, and a parameter which is a function of one of these readings and which indicates ischaemia or global hypokinetic function is generated.
Owner:UNIV OSLO HF
Systems and methods for use by implantable medical devices for detecting and discriminating stroke and cardiac ischemia using electrocardiac signals
Techniques are provided for detecting and distinguishing stroke and cardiac ischemia based on electrocardiac signals. In one example, the device senses atrial and ventricular signals within the patient along a set of unipolar sensing vectors and identifies certain morphological features within the signals such as PR intervals, ST intervals, QT intervals, T-waves, etc. The device detects changes, if any, within the morphological features such as significant shifts in ST interval elevation or an inversion in T-wave shape, which are indicative of stroke or cardiac ischemia. By selectively comparing changes detected along different unipolar sensing vectors, the device distinguishes or discriminates stroke from cardiac ischemia within the patient. The discrimination may be corroborated using various physiological and hemodynamic parameters. In some examples, the device further identifies the location of the ischemia within the heart. In still other examples, the device detects cardiac ischemia occurring during stroke.
Owner:PACESETTER INC
Application of arachidonate lipoxygenase (ALOX)12 inhibitor to preparation of heart ischemia reperfusion injury (IRI) therapeutic drug
ActiveCN110464844AOrganic active ingredientsPharmaceutical non-active ingredientsCardiac ischaemiaArachidonate 5-lipoxygenase
The invention provides application of arachidonate lipoxygenase (ALOX)12 inhibitor to preparation of a heart ischemia reperfusion injury (IRI) therapeutic drug. Through research, it is found that in hepatic ischemia reperfusion injury (HIRI), the ALOX12 protein expression quantity and the mRNA expression quantity are changed significantly, the change of ALOX5 and the change of ALOX15 have no difference, and it shows that compared with other ALOX members, the ALOX12 has the larger effect on the HIRI; through ALOX12 overexpression, activity decreasing of liver cells and kidney cells due to anaerobic and reoxygenation treatment is aggravated, and an inflammatory reaction of the liver cells is promoted; and through ALOX12 under-expression, activity decreasing of cardiac muscle cells due to anaerobic and reoxygenation treatment can be relieved, and the results show that the ALOX12 can promote IRI of organs such as the liver, the heart and the kidney, and occurrence and development of otherinflammatory reactions in the organs. On the basis, the ALOX12 can serve as a treatment target point of the IRI, IRI-related diseases, inflammatory diseases and cell death-related diseases.
Owner:武汉赛莱亚生物科技有限公司
Uses of kappa-conotoxin PVIIA
The invention relates to uses of kappa-conotoxin PVIIA (κ-PVIIA), analogs and derivatives for activating ATP-sensitive K+ channels. The activation of ATP-sensitive K+ channels is useful for opening KATP channels which can be used to treat a wide range of disease and injury states, including cerebral and cardiac ischemia and asthma.
Owner:COGNETIX
Systems and methods for use by implantable medical devices for detecting and discriminating stroke and cardiac ischemia using electrocardiac signals
Techniques are provided for detecting and distinguishing stroke and cardiac ischemia based on electrocardiac signals. In one example, the device senses atrial and ventricular signals within the patient along a set of unipolar sensing vectors and identifies certain morphological features within the signals such as PR intervals, ST intervals, QT intervals, T-waves, etc. The device detects changes, if any, within the morphological features such as significant shifts in ST interval elevation or an inversion in T-wave shape, which are indicative of stroke or cardiac ischemia. By selectively comparing changes detected along different unipolar sensing vectors, the device distinguishes or discriminates stroke from cardiac ischemia within the patient. The discrimination may be corroborated using various physiological and hemodynamic parameters. In some examples, the device further identifies the location of the ischemia within the heart. In still other examples, the device detects cardiac ischemia occurring during stroke.
Owner:PACESETTER INC
A two-electrode electrocardiogram lead intelligent positioning system
ActiveCN108498091BCorrect long-term ECG dynamic monitoringImprove the success rate of rescueSensorsMedical equipmentCardiac ischaemiaMedicine
The invention relates to a two-electrode electrocardiogram lead intelligent positioning system. The electrocardiographic electrode position automatic correction method of the intelligent positioning system includes the following steps: step S1, artificial intelligence learning of normal electrocardiogram signal characteristics, and establishing a user's own benchmark; step S2, the user records the waveform during measurement, analyzes the waveform, extracts the same parameters as the reference waveform, compares the reference parameters, and calculates the comprehensive error; step S3, the user records the digital information of the electrocardiogram of the comprehensive error in step S2 by himself for artificial intelligence comparison , Intelligent assistant guides the correct placement of the electrode leads. Its technical effect is: intelligently assisting in guiding the correct placement of the electrode leads, so as to realize the correct long-term ECG dynamic monitoring of the two-electrode ECG monitor, and early and effectively identify cardiovascular risk events such as cardiac ischemia and malignant arrhythmia , and ultimately improve the success rate of rescue of cardiovascular risk events and reduce their mortality.
Owner:ZHONGSHAN HOSPITAL FUDAN UNIV +1
Chinese medicine adhesive film for preventing and treating coronary heart disease and angina pectoris and its preparing method
InactiveCN1262299CHydroxy compound active ingredientsSheet deliveryCardiac ischaemiaCoronary heart disease
The Chinese medicine adhesive film for preventing and treating coronary heart disease and angina pectoris consists of back lining material, medicine layer and protecting film. The medicine layer consists of skeleton supplementary material, effective Chinese medicine extractive and plasticizer; and the effective Chinese medicine extractive is ointment of extractive of Chuanxiong rhizome, sandalwood, nutagrass flatsedge rhizome, dalbergia wood, frankincense, kudzu vine root, etc. The Chinese medicine adhesive film is adhered to left chest for transdermal absorption to act on heart, and can dilate coronary blood vessel, improve blood flow of coronary blood vessel, improve heart function and prevent hidden coronary heart disease.
Owner:马德林
Method of treating ischemia/reperfusion injuries to a heart with netrin-1
InactiveUS9050298B2Increasing phosphorylation of ERK1/2Reducing loss of NO in a cardiac tissueOrganic active ingredientsPeptide/protein ingredientsProgenitorCardiac ischaemia
Disclosed herein are methods for treating, inhibiting, or reducing ischemia / reperfusion injury of a cardiac tissue; increasing phosphorylation of ERK1 / 2 and / or eNOS in a cardiac tissue; treating, inhibiting, or reducing loss of NO; treating, inhibiting, or reducing uncoupling of NOS; increasing recoupling of NOS; treating, inhibiting, or reducing loss of DCC protein and mRNA expression in a cardiac tissue; decreasing or reducing the infarct size of a heart resulting from ischemia / reperfusion injury; decreasing or reducing superoxide production by a cardiac tissue caused by ischemia / reperfusion injury; treating, inhibiting, or reducing neointimal formation and restenosis; treating, inhibiting, or reducing apoptosis of mobilized endothelial progenitor cells; or a combination thereof of a blood vessel (such as an artery, a coronary artery, a vein, or a capillary) or a portion of the blood vessel in a subject which comprise the administration of netrin-1.
Owner:RGT UNIV OF CALIFORNIA
Chelator-targeting ligand conjugates for cardiovascular imaging
InactiveUS20170281806A1High sensitivityStrong specificityRadioactive preparation carriersDrug compositionsCardiac ischaemiaMethod of images
Disclosed are methods of imaging a site in a heart of a subject to detect cardiovascular disease that involve stressing a subject, administering to the stressed subject an effective amount of a radionuclide-labeled chelator-glucose analog conjugate, and imaging the heart of the subject by detecting a signal generated by the conjugate in the heart of the subject. Also disclosed are methods of imaging a peripheral blood vessel in a subject by using a detectable amount of a radionuclide-labeled chelator-glucose analog conjugate. Also disclosed are methods of distinguishing a false positive nuclear cardiology scan from a true positive nuclear cardiology scan, methods of diagnosing congestive heart failure or cardiac ischemia that involve imaging a subject that has been administered a radionuclide-labeled chelator-glucose analog conjugate, and methods to distinguish viable from nonviable myocardium.
Owner:CELLPOINT
Mitochondrial lipid permeable iron chelators for treating and preventing ischemia/reperfusion (I/R) injury in the heart following an ischemic event
ActiveUS10258612B2Protects ischemiaProtect from harmAmide active ingredientsLipid formationCardiac ischaemia
Disclosed are methods and compositions for treating or preventing a disease or disorder responsive to a decrease in baseline mitochondrial iron in a subject in need thereof. The methods typically include administering a pharmaceutical composition comprising a mitochondrial permeable iron chelator to the subject.
Owner:NORTHWESTERN UNIV
Application of ridecevir in preparation of medicine for preventing and treating reperfusion injury
ActiveCN114146091AExpanded indicationsHigh application potentialOrganic active ingredientsCardiovascular disorderCardiac ischaemiaPharmaceutical drug
The invention discloses an application of Redesivir (Redesivir) in a medicine for preventing and treating reperfusion injury, especially heart reperfusion injury. The invention verifies the great potential of the ridecavir as the medicine for preventing and treating the heart ischemia reperfusion injury, discloses a good protection curative effect of the ridecavir on the heart ischemia reperfusion injury for the first time, provides an effective novel potential alternative medicine for clinical prevention and treatment of the reperfusion injury, expands the adaptation of the ridecavir, and has a good application prospect in prevention and treatment of the heart ischemia reperfusion injury. The application potential and the market prospect of the ridecevir are greatly improved.
Owner:北京箭牧科技有限公司
Novel application of sodium sulfite
InactiveCN102462695AReduce perfusion flowIncrease success rateDough treatmentRespiratory disorderCardiac ischaemiaDisease
The invention discloses a novel application of sodium sulfite (Na2SO3), that is, an application in preparing medicines, health products, functional drinks or functional food for preventing hypoxia-induced injury and / or diseases related to ischemia-hypoxia. According to the invention, by using Na2SO3 as an active component in preparing medicines, health products, functional drinks or functional food for preventing hypoxia-induced injury and / or diseases related to ischemia-hypoxia, the body can be in a hypoxia (such as high altitude hypoxia, mine hypoxia, and the like ) preconditioning state, thus the purpose of preventing hypoxia-induced injury and / or diseases related to ischemia-hypoxia (such as high altitude pulmonary edema, high altitude cerebral edema, cerebral ischemia, cardiac ischemia, respiratory distress, and the like) can be achieved. The medicines disclosed herein have the following advantages: 1) obvious curative effect; 2) no toxic and side effect, and high safety; 3) low price of Na2SO3; and 4) convenience in drug use (convenience in carrying and taking).
Owner:INST OF RADIATION MEDICINE ACAD OF MILITARY MEDICAL SCI OF THE PLA +1
Traditional Chinese medicine composition and preparation method thereof
InactiveCN106361802AEnhance immune functionImprove ejection fractionUnknown materialsGranular deliveryCardiac ischaemiaCoronary artery disease
Owner:SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M
Methods of diagnosis and treatment
A method for diagnosing a cardiac ischemic event and a kit for detecting biomarkers used in the method. Also provided is a method for treating a PPAR-related disorder by administering a pharmaceutical composition containing one or more long chain fatty acids.
Owner:THERANOSTICS LAB
Systems and methods for st segment stability discrimination during cardiac ischemia detection for use with implantable medical devices
Techniques are provided for discriminating episodes of cardiac ischemia indicated based on shifts in ST segment elevation from false detections due to atrial fibrillation (AF) or other confounding factors such as premature ventricular contractions (PVCs.) In an example for use with a single-chamber device, in response to a possible ischemic event, the single-chamber device assesses ventricular stability based an examination of ventricular intracardiac electrogram (IEGM) signals. If the ventricular IEGM is unstable due to paroxysmal AF or frequent PVCs, the ischemic event is rejected as a false detection. Otherwise, the device responds to the event by, for example, generating warning signals, recording diagnostic data or controlling device therapy. The stability discrimination techniques are particularly advantageous for use within single-chamber devices that lack automatic mode switching but are also beneficial within at least some dual-chamber devices or multi-chamber systems.
Owner:PACESETTER INC
Deuterated tetrapeptides that target mitochondria
InactiveUS20200361987A1Peptide/protein ingredientsPeptide preparation methodsCardiac ischaemiaElamipretide
Disclosed are deuterated analogs of SBT-20 and elamipretide (MTP-131). The compounds are useful for the treatment and prevention of ischemia-reperfusion injury (e.g., cardiac ischemia-reperfusion injury) or myocardial infarction.
Owner:STEALTH BIOTHERAPEUTICS INC
Mitochondria protecting agents for treating mitochondria associated diseases
The present invention relates generally to mitochondria protecting agents for treating diseases in which mitochondrial dysfunction leads to tissue degeneration and, more specifically, to compounds, compositions and methods related to the same. The methods of this invention involve administration of a pharmaceutically effective amount of a mitochondria protecting agent to a warm-blooded animal in need thereof, and composition of this invention contain a mitochondria protecting agent in combination with a pharmaceutically acceptable carrier or diluent. Mitochondrial associated diseases which may be treated by the present invention include (but are not limited to) Alzheimer's Disease, diabetes mellitus. Parkinson's Disease, neuronal and cardiac ischemia. Huntington's disease and stroke.
Owner:GHOSH SOUMITRA S +3
Treatments for heart failure and cardiac ischaemic reperfusion injury
The present invention relates to the use of extracorporeal cardiac Shockwave therapy in the treatment or prophylaxis of heart disease, in particular the invention provides a dipeptidyl peptidase-4 (DPP-4) inhibitor, or a pharmaceutical composition containing said inhibitor, for use in: (a) treating or preventing heart failure; or (b) treating cardiac ischaemic reperfusion injury, in a subject, wherein said subject has been administered extracorporeal cardiac Shockwave therapy and wherein said inhibitor is for administration prior to, simultaneously with, and / or after administration of said Shockwave therapy.
Owner:萨洛蒙纳若登
Features
- R&D
- Intellectual Property
- Life Sciences
- Materials
- Tech Scout
Why Patsnap Eureka
- Unparalleled Data Quality
- Higher Quality Content
- 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com